Shweta Joshi

Title(s)Assistant Adjunct Professor, Pediatrics
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Central Drug Research Institute , Lucknow, IndiaPhD2010Biochemistry

    Collapse Overview 
    Collapse Overview
    The primary goal of our research is to understand molecular mechanisms regulating tumor growth, inflammation and metastasis. Our laboratory is focused on the study of signaling cascades that regulate recruitment and activation of immunosuppressive myeloid cells in solid tumors with special focus on neuroblastoma and pancreatic adenocarcinoma.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    Perioperative Fostamatinib + Chemotherapy for Resectable Pancreatic Cancer
    Cure Bound Cure PrizeJul 1, 2024 - Jun 30, 2027
    Role: Co-PI
    Syk-Targeted Therapy with Fostamatinib: A Promising Avenue to Enhance Chemotherapy Response in Pancreatic Cancer
    Lustgarten Clinical Accelrator Initiative GrantJul 1, 2024 - Jun 30, 2027
    Role: Co-PI
    Targeting Syk to enhance anti-tumor immune responses in neuroblastoma
    NIH R01NS122835Aug 1, 2021 - Apr 30, 2026
    Role: PI
    Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity
    NIH K22CA229594Dec 1, 2019 - Nov 30, 2022
    Role: PI

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. New insights into SYK targeting in solid tumors. Trends Pharmacol Sci. 2024 Oct; 45(10):904-918. Joshi S. PMID: 39322438.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    2. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2023 08 15; 83(16):2675-2689. Rohila D, Park IH, Pham TV, Weitz J, Hurtado de Mendoza T, Madheswaran S, Ishfaq M, Beaman C, Tapia E, Sun S, Patel J, Tamayo P, Lowy AM, Joshi S. PMID: 37306759; PMCID: PMC10416758.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    3. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma. Front Immunol. 2023; 14:1148317. Rohila D, Park IH, Pham TV, Jones R, Tapia E, Liu KX, Tamayo P, Yu A, Sharabi AB, Joshi S. PMID: 37350973; PMCID: PMC10283071.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    4. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharmacol Ther. 2022 07; 235:108114. Joshi S, Sharabi A. PMID: 35122833; PMCID: PMC9189042.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    5. The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma. iScience. 2021 Sep 24; 24(9):102931. Pal D, Vann KR, Joshi S, Sahar NE, Morales GA, El-Gamal D, Kutateladze TG, Durden DL. PMID: 34557659; PMCID: PMC8445847.
      View in: PubMed   Mentions: 4  
    6. BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma. Cancers (Basel). 2021 Feb 16; 13(4). Ishfaq M, Pham T, Beaman C, Tamayo P, Yu AL, Joshi S. PMID: 33669187; PMCID: PMC7919651.
      View in: PubMed   Mentions: 12  
    7. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma. Front Immunol. 2020; 11:1947. Liu KX, Joshi S. PMID: 32983125; PMCID: PMC7493646.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    8. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020; 6(1):49. Burgoyne AM, Vann KR, Joshi S, Morales GA, Vega FM, Singh A, Pal D, Merati AB, Kutateladze TG, Durden DL. PMID: 32793389; PMCID: PMC7385619.
      View in: PubMed   Mentions: 5  
    9. Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. Cancers (Basel). 2020 Jul 25; 12(8). Joshi S. PMID: 32722460; PMCID: PMC7465822.
      View in: PubMed   Mentions: 25  
    10. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 03; 19(3):755-764. Joshi S, Liu KX, Zulcic M, Singh AR, Skola D, Glass CK, Sanders PD, Sharabi AB, Pham TV, Tamayo P, Shiang D, Dinh HQ, Hedrick CC, Morales GA, Garlich JR, Durden DL. PMID: 31974273; PMCID: PMC7450492.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    11. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. Mol Cancer Ther. 2019 06; 18(6):1036-1044. Joshi S, Singh AR, Liu KX, Pham TV, Zulcic M, Skola D, Chun HB, Glass CK, Morales GA, Garlich JR, Durden DL. PMID: 31018997; PMCID: PMC6893301.
      View in: PubMed   Mentions: 26     Fields:    Translation:AnimalsCells
    12. Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. J Oncol. 2019; 2019:5245034. Joshi S, Durden DL. PMID: 30853982; PMCID: PMC6377965.
      View in: PubMed   Mentions: 44  
    13. Erratum to: Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. Thromb Haemost. 2019 09; 119(9):1546. Cooke EJ, Zhou JY, Wyseure T, Joshi S, Bhat V, Durden DL, Mosnier LO, von Drygalski A. PMID: 30071568.
      View in: PubMed   Mentions:    Fields:    
    14. Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. Thromb Haemost. 2018 06; 118(6):1036-1047. Cooke EJ, Zhou JY, Wyseure T, Joshi S, Bhat V, Durden DL, Mosnier LO, von Drygalski A. PMID: 29847841; PMCID: PMC6191040.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    15. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. J Biol Chem. 2018 04 20; 293(16):5808-5820. Campbell GR, Bruckman RS, Herns SD, Joshi S, Durden DL, Spector SA. PMID: 29475942; PMCID: PMC5912471.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    16. Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. PLoS One. 2017; 12(8):e0182851. Joshi S, Singh AR, Wong SS, Zulcic M, Jiang M, Pardo A, Selman M, Hagood JS, Durden DL. PMID: 28817691; PMCID: PMC5560537.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    17. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A. 2017 02 14; 114(7):E1072-E1080. Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG. PMID: 28137841; PMCID: PMC5320964.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    18. Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 2017 Aug 08; 8(32):52193-52210. Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL. PMID: 28881723; PMCID: PMC5581022.
      View in: PubMed   Mentions: 16     Fields:    
    19. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 11; 15(11):2553-2562. Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. PMID: 27496136; PMCID: PMC5278767.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    20. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One. 2016; 11(3):e0150836. Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL. PMID: 26938241; PMCID: PMC4777592.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    21. Vascular remodeling underlies rebleeding in hemophilic arthropathy. Am J Hematol. 2015 Nov; 90(11):1027-35. Bhat V, Olmer M, Joshi S, Durden DL, Cramer TJ, Barnes RF, Ball ST, Hughes TH, Silva M, Luck JV, Moore RE, Mosnier LO, von Drygalski A. PMID: 26257191; PMCID: PMC4618067.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    22. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol. 2015 Mar; 75(3):595-608. Joshi S, Singh AR, Durden DL. PMID: 25578041.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    23. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014; 14(1):105. Singh AR, Joshi S, George E, Durden DL. PMID: 25425962; PMCID: PMC4243316.
      View in: PubMed   Mentions: 12  
    24. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014 Oct; 12(10):1520-31. Joshi S, Singh AR, Zulcic M, Durden DL. PMID: 25103499.
      View in: PubMed   Mentions: 72     Fields:    Translation:AnimalsCells
    25. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014 Aug; 36(6):451-7. Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL. PMID: 24309609; PMCID: PMC4356196.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    26. MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem. 2014 Aug 15; 289(33):22785-22797. Joshi S, Singh AR, Durden DL. PMID: 24982421; PMCID: PMC4132784.
      View in: PubMed   Mentions: 55     Fields:    Translation:AnimalsCells
    27. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Exp Cell Res. 2014 Sep 10; 327(1):78-90. Singh AR, Peirce SK, Joshi S, Durden DL. PMID: 24881819.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    28. A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis. BMC Immunol. 2014 May 07; 15:18. Joshi S, Singh AR, Zulcic M, Durden DL. PMID: 24886428; PMCID: PMC4017086.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    29. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS One. 2014; 9(4):e95893. Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden DL. PMID: 24770346; PMCID: PMC4000195.
      View in: PubMed   Mentions: 68     Fields:    Translation:AnimalsCells
    30. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. J Neurooncol. 2014 Jan; 116(1):89-97. Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT. PMID: 24162827; PMCID: PMC3896301.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    31. Guanidine hydrochloride and urea-induced unfolding of Brugia malayi hexokinase. Eur Biophys J. 2010 Jan; 39(2):289-97. Singh AR, Joshi S, Arya R, Kayastha AM, Saxena JK. PMID: 19756573.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    32. Molecular cloning and characterization of Brugia malayi hexokinase. Parasitol Int. 2008 Sep; 57(3):354-61. Singh AR, Joshi S, Arya R, Kayastha AM, Srivastava KK, Tripathi LM, Saxena JK. PMID: 18499511.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    33. Molecular cloning and characterization of Plasmodium falciparum transketolase. Mol Biochem Parasitol. 2008 Jul; 160(1):32-41. Joshi S, Singh AR, Kumar A, Misra PC, Siddiqi MI, Saxena JK. PMID: 18456347.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    34. DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes. Inorg Chem. 2007 Dec 10; 46(25):10869-76. Singh SK, Joshi S, Singh AR, Saxena JK, Pandey DS. PMID: 18001110.
      View in: PubMed   Mentions: 4     Fields:    
    Shweta's Networks
    Concepts (224)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (21)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California